Purchase Order 75N93021P01445
- Not listed
- This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH), to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The $16,199.95 contract is for the delivery of BIOLEGEND antibodies to support NIAID's research initiatives, which may include studies related to COVID-19, immunology, and other disease areas. The contract does not...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>
- <p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>
- This is a firm fixed-price purchase order contract awarded by the National Institute on Aging (NIA), a civilian agency within the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, proteins, and other scientific research products located in San Diego, California. The contract is for the procurement of biological and reagent materials, specifically Biolegend flow cytometer antibodies, with a ceiling value of $14,042.25...
- This $9,343.50 firm-fixed-price purchase order was awarded to Biolegend, Inc., a for-profit manufacturer and supplier of biomedical reagents, antibodies, proteins, and other products supporting life science research and drug discovery. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The award supports Biolegend's provision of specialized products, including oligonucleotide-tagged...
- This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $19,987.50 on August 24, 2020, for antibodies. Performance is located in San Diego, California with completion scheduled for September 23, 2020. This firm fixed-price acquisition carries no small business set-aside.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a $56,762.00 firm-fixed-price purchase order to Biolegend, Inc. for the supply of various biological research products, including Alexa Fluor 700 anti-human IFN-γ and several Brilliant Violet-labeled antibodies for human cellular markers. This acquisition was processed under Simplified Acquisition Procedures without a small business set-aside. Biolegend, a...
This purchase order, awarded to Biolegend, Inc. on September 17, 2021, represents an administrative action by the National Institute of Allergy and Infectious Diseases (NIAID) to de-obligate $10,568 in unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a). The contract, which was ultimately completed on October 17, 2021, is structured as a firm fixed-price purchase order with no small business set-aside designation. The place of performance is located in Rockville, Maryland, where NIAID maintains its primary facilities. Biolegend, Inc., a manufacturer of biomedical reagents, antibodies, proteins, and specialized scientific research products based in San Diego, California, serves as the prime contractor. The company has an established history of providing high-quality biological research materials to federal agencies, particularly to various NIH institutes including NIAID. This de-obligatory action reflects routine fiscal year-end fund management procedures and does not represent a new procurement of goods or services, but rather the administrative closure of previously obligated funding prior to the September 30, 2026 expiration of the fiscal year 2021 period of availability.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Funding Only Action | 0$ | 3/10/26 | |
| Not listed | Not listed | $10.6k | 9/17/21 |